(Q24202572)

6

object named as

Giovanni FM Strippoli

0 references

Angela Webster

7

object named as

Angela C Webster

0 references

Robert S Flanc

4

object named as

Robert S Flanc

0 references

author name string

Lorna Henderson

1

0 references

Philip Masson

2

0 references

Matthew A Roberts

Cochrane Database of Systematic Reviews

5

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

NIH conference. Systemic lupus erythematosus: evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil in the treatment of lupus nephritis--7 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Value of a complete or partial remission in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Severe lupus nephritis: racial differences in presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

The prognosis of severe lupus nephritis based on the Modification of Diet in Renal Disease (MDRD) study estimated glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Cyclophosphamide in lupus nephritis: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Fish oil in lupus nephritis: clinical findings and methodological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Improvement of renal function with selective thromboxane antagonism in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

[Effect of intravenous drip infusion of cyclophosphamide with high-dose Astragalus injection in treating lupus nephritis].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Outcomes in African Americans and Hispanics with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Treatment for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

[Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Misoprostol and Prednisone Treatment of Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Bladder cancer after cyclophosphamide therapy for lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Approach to lupus nephritis based upon randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Flares in lupus nephritis: Incidence, impact on renal survival and management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Treatment of Lupus Nephritis with Prednisone and Combined Prednisone and Azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002922.PUB3

7 January 2021

10.1002/14651858.CD002922.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23235592

1 reference

Consolidated OpenCitations Corpus – April 2017